Cargando…
Effectiveness and safety of Dupilumab for the treatment at 104 weeks of recalcitrant bullous pemphigoid
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10549962/ https://www.ncbi.nlm.nih.gov/pubmed/37881049 http://dx.doi.org/10.1111/srt.13488 |
| _version_ | 1785115431819804672 |
|---|---|
| author | Manzo Margiotta, Flavia Fidanzi, Cristian Bevilacqua, Matteo Janowska, Agata Romanelli, Marco Manni, Elisabetta |
| author_facet | Manzo Margiotta, Flavia Fidanzi, Cristian Bevilacqua, Matteo Janowska, Agata Romanelli, Marco Manni, Elisabetta |
| author_sort | Manzo Margiotta, Flavia |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10549962 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-105499622023-10-05 Effectiveness and safety of Dupilumab for the treatment at 104 weeks of recalcitrant bullous pemphigoid Manzo Margiotta, Flavia Fidanzi, Cristian Bevilacqua, Matteo Janowska, Agata Romanelli, Marco Manni, Elisabetta Skin Res Technol Letter to the Editor John Wiley and Sons Inc. 2023-10-04 /pmc/articles/PMC10549962/ /pubmed/37881049 http://dx.doi.org/10.1111/srt.13488 Text en © 2023 The Authors. Skin Research and Technology published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| spellingShingle | Letter to the Editor Manzo Margiotta, Flavia Fidanzi, Cristian Bevilacqua, Matteo Janowska, Agata Romanelli, Marco Manni, Elisabetta Effectiveness and safety of Dupilumab for the treatment at 104 weeks of recalcitrant bullous pemphigoid |
| title | Effectiveness and safety of Dupilumab for the treatment at 104 weeks of recalcitrant bullous pemphigoid |
| title_full | Effectiveness and safety of Dupilumab for the treatment at 104 weeks of recalcitrant bullous pemphigoid |
| title_fullStr | Effectiveness and safety of Dupilumab for the treatment at 104 weeks of recalcitrant bullous pemphigoid |
| title_full_unstemmed | Effectiveness and safety of Dupilumab for the treatment at 104 weeks of recalcitrant bullous pemphigoid |
| title_short | Effectiveness and safety of Dupilumab for the treatment at 104 weeks of recalcitrant bullous pemphigoid |
| title_sort | effectiveness and safety of dupilumab for the treatment at 104 weeks of recalcitrant bullous pemphigoid |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10549962/ https://www.ncbi.nlm.nih.gov/pubmed/37881049 http://dx.doi.org/10.1111/srt.13488 |
| work_keys_str_mv | AT manzomargiottaflavia effectivenessandsafetyofdupilumabforthetreatmentat104weeksofrecalcitrantbullouspemphigoid AT fidanzicristian effectivenessandsafetyofdupilumabforthetreatmentat104weeksofrecalcitrantbullouspemphigoid AT bevilacquamatteo effectivenessandsafetyofdupilumabforthetreatmentat104weeksofrecalcitrantbullouspemphigoid AT janowskaagata effectivenessandsafetyofdupilumabforthetreatmentat104weeksofrecalcitrantbullouspemphigoid AT romanellimarco effectivenessandsafetyofdupilumabforthetreatmentat104weeksofrecalcitrantbullouspemphigoid AT mannielisabetta effectivenessandsafetyofdupilumabforthetreatmentat104weeksofrecalcitrantbullouspemphigoid |